Literature DB >> 17589808

Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy.

Carol S Yu1, Suk I Chiu, Chi S Ng, Henry H Chan, Raymond K Tse.   

Abstract

PURPOSE: Conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is a rare, low-grade, non-Hodgkin's B-cell lymphoma. We report our successful management of localized conjunctival MALT lymphoma with topical Mitomycin C (MMC).
METHODS: This is a case report. A 35-year-old woman had a mobile painless 1.5x1-cm mass in the left conjunctiva for 2 years. Examination revealed two similar masses in the right conjunctiva. Incisional biopsy for immunohistochemical stain and PCR of the left conjunctival mass showed MALT lymphoma. She was given four courses of topical 0.04% MMC eyedrops. There was transient conjunctival injection and superficial punctate keratopathy which responded to topical steroid and lubricant.
RESULTS: The lesions regressed completely after the fourth cycle of treatment and repeat biopsy confirmed complete remission.
CONCLUSION: This is the first report of localized conjunctival MALT lymphoma being successfully treated by topical MMC with minimal local controllable side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589808     DOI: 10.1007/s10792-007-9102-5

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  8 in total

1.  Conjunctival lymphoid tumors: clinical analysis of 117 cases and relationship to systemic lymphoma.

Authors:  C L Shields; J A Shields; C Carvalho; P Rundle; A F Smith
Journal:  Ophthalmology       Date:  2001-05       Impact factor: 12.079

2.  Lymphomas of mucosa-associated lymphoid tissue (MALT).

Authors:  P G Isaacson
Journal:  Histopathology       Date:  1990-06       Impact factor: 5.087

3.  Local chemotherapy with interferon-alpha for conjunctival mucosa-associated lymphoid tissue lymphoma: a preliminary report.

Authors:  M A Blasi; F Gherlinzoni; G Calvisi; P Sasso; M Tani; M Cellini; E Balestrazzi
Journal:  Ophthalmology       Date:  2001-03       Impact factor: 12.079

4.  Ocular morbidity after radiotherapy of orbital and conjunctival lymphoma.

Authors:  E M Bessell; J M Henk; R A Whitelocke; J E Wright
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

5.  Mucosal-associated lymphoid tissue lymphoma of the conjunctiva.

Authors:  S Hardman-Lea; M Kerr-Muir; A C Wotherspoon; W T Green; A Morell; P G Isaacson
Journal:  Arch Ophthalmol       Date:  1994-09

6.  Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva.

Authors:  Holger Nückel; Daniel Meller; Klaus-Peter Steuhl; Ulrich Dührsen
Journal:  Eur J Haematol       Date:  2004-10       Impact factor: 2.997

7.  Inhibition of corneal epithelial wound healing. A comparative study of mitomycin C and 5-fluorouracil.

Authors:  H Ando; T Ido; Y Kawai; T Yamamoto; Y Kitazawa
Journal:  Ophthalmology       Date:  1992-12       Impact factor: 12.079

8.  Mitomycin C therapy for corneal intraepithelial neoplasia.

Authors:  J Frucht-Pery; Y Rozenman
Journal:  Am J Ophthalmol       Date:  1994-02-15       Impact factor: 5.258

  8 in total
  4 in total

1.  [Follicular conjunctivitis of unknown origin].

Authors:  S Goebels; A K Hasenfus; B K Kellner; U Löw; B Seitz
Journal:  Ophthalmologe       Date:  2012-01       Impact factor: 1.059

2.  Ocular surface tumors.

Authors:  Ihab Saad Othman
Journal:  Oman J Ophthalmol       Date:  2009-01

3.  Treatment of MALT lymphoma of the conjunctiva with intralesional rituximab supplemented with autologous serum.

Authors:  Andrés J M Ferreri; Marianna Sassone; Elisabetta Miserocchi; Silvia Govi; Caterina Cecchetti; Matteo E Corti; Silvia Mappa; Luca Arcaini; Francesco Zaja; Giuseppe Todeschini; Donato Mannina; Teresa Calimeri; Salvatore Perrone; Maurilio Ponzoni; Giulio Modorati
Journal:  Blood Adv       Date:  2020-03-24

4.  Prediction of cancer drugs by chemical-chemical interactions.

Authors:  Jing Lu; Guohua Huang; Hai-Peng Li; Kai-Yan Feng; Lei Chen; Ming-Yue Zheng; Yu-Dong Cai
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.